Multifactor Assessment of Metabolic Syndrome Risk in Uzbek Children and Adolescents with Obesity

Gulnara N. Rakhimova¹,², PhD, ScD; Shakhnoza Sh. Azimova¹*

¹ Center for the Scientific and Clinical Study of Endocrinology; ² Tashkent Institute of Post-Graduate Study, Department of Endocrinology; Tashkent, Republic of Uzbekistan

*Corresponding author: Shakhnoza Sh.Azimova. Center for the Scientific and Clinical Study of Endocrinology;. Tashkent, Uzbekistan. E-mail: shahnoz74@yandex.com

Published: March 16, 2016. DOI: 10.21103/Article6(1)_OA10

Abstract: 

Metabolic syndrome (MetS) contributes to early atherosclerotic changes of blood vessels and type 2 diabetes mellitusnot only among adults, but among children and adolescents, causing onset and progression of severe diseases resulting in early disablement and death. Multifactor analysis of MetS risk in Uzbek children and adolescents with exogenous-constitutional obesity (ECO) was the purpose of the study. The study included 100 Uzbek children and adolescents with ECO aged from 6 to 16 (mean age 11.7±0.25 years)—54(54.0%) boys and 46(46.0%) girls. Prognostic matrix was made up by means of a modification of Bayesian probability by E. Shigan (1986). Mathematical analysis confirmed a high degree of risk for MetS onset and progression in obese patients with disorders of lipid profile and hemodynamics. MetS risk is 8.2 times higher with levels of HDL-C <1.03 mmol/l, 3.6 times higher in patients with concentrations of TG ≥1.7 mmol/l, and 2 times higher in those with systolic arterial pressure (SAD) values ≥130 mmHg. The findings from our study confirm a high predictive value of HDL-C levels <1.03 mmol/l, TG ≥1.7 mmol/l and SAD for MetS onset and progression in Uzbek children and adolescents with obesity. Taking into account the integral assessment of MetS risk factors with waist circumference reference values established for the Uzbek pediatric population helped determine risk factors with very high disease dependence, such as atherogenic index >3.0, HbA1c >6.7%, and obesity onset before 5 years of age.

Keywords: 
obesity; metabolic syndrome; adolescents; children.
References: 

1.Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents-an IDF consensus report. Pediatric Diabetes.2007; 8(5):299-306.

2.Bokova TA. Metabolic syndrome in children: peculiarities of formation and clinical course, approaches to diagnosis, prevention and treatment. Abstract of ScD Thesis. Moscow; 2014. [in Russian].

3.Leontieva IV. Diagnosis and treatment of metabolic syndrome in pediatric practice. Pediatrics. 2011; 2:13-23 [in Russian].

4.Sinitsyn P.A. Metabolic syndrome in children and adolescents. Clinical-pathogenetic parallels. Abstract of ScD Thesis. Moscow; 2011. [in Russian].

5.Rakhimova GN, Azimova ShSh. Integral assessment of risk factors for metabolic syndrome in children and adolescents with obesity. International Endocrinological Journal. 2012; (43):77-81 [in Russian].

6.Azimova ShSh, Rakhimova GN. Determination of metabolic syndrome risk by waist circumference in Uzbek children and adolescents. Patent No. DGU 02583 (2012).

7.Azimova Sh, Rakhimova G. Waist circumference percentiles in a nationally representative sample of 7-18 years old Uzbek children and adolescents. Medical and Health Science Journal. 2013; 14 (3):123-27.

8.Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents.Pediatrics. 1996; 98 (4 Pt 1): 649–58.

9.Shigan EN. Methods for prediction and modeling in social-hygienic studies. M.: Meditsina; 1986.  [in Russian].

10.Babanov S.A., Vorobyova E.V., Gailis P.V., Agarkova I.A. Epidemiology of non-infectious diseases: problems of this stage. Profilakt Meditsina 2011; (3):11-14 [in Russian].

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2016; 6(1):48-52. © 2016 International Medical Research and Development Corporation. All rights reserved.